AMRX vs BHC vs ELTP Stock Comparison

Amneal Pharmaceuticals, Bausch Health Companies and Elite Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group

Head to Head

11 decided of 12

Elite Pharmaceuticals leads on 7 of the 12 questions below (Elite Pharmaceuticals 7, Amneal Pharmaceuticals 3, Bausch Health Companies 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMRXBHCELTPLeader
Larger companyMarket capitalisation $7.12B $3.18B $401.23M AMRX
Cheaper on earningsLower P/E, profitable companies only 53.4x -3.8x 6.7x ELTP
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.4x 1.6x — BHC
Faster revenue growthRevenue growth, trailing twelve months +8.9% +10.8% +17.8% ELTP
More profitableNet margin, trailing twelve months 4.2% -7.6% 41.6% ELTP
Better return on capitalReturn on invested capital 14.3% 6.4% 27.6% ELTP
Less leveragedLower net debt / EBITDA 4.3x 7.4x -0.9x ELTP
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +85.6% +26.1% -50.7% AMRX
Better 5-year returnAnnualised price return, 5 years +32.7%/yr -20.6%/yr +52.6%/yr ELTP
Less volatileAnnualised volatility, 1 year 34.3% 59.5% 66.6% AMRX
Higher overall scoreMean of the five percentile scores vs peers 69/100 65/100 88/100 ELTP

Percentile Scorecard

AMRXBHCELTP

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMRXBHCELTP
Valuation 90 #69 of 660 99 #6 of 660 94 #40 of 660
Growth 70 #189 of 619 57 #265 of 619 85 #96 of 619
Profitability 87 #80 of 595 86 #83 of 595 91 #52 of 595
Financial Health 11 #606 of 683 16 #577 of 683 81 #130 of 683
Shareholder Returns 89 #53 of 459 – 87 #63 of 459
Overall 69 65 88
  • AMRX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • BHC ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ELTP ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMRXBHCELTPSPY
1 month +13.1%+41.8%+32.0% -2.0%
3 months +17.8%+28.3%+6.5% -2.8%
6 months +79.2%+54.1%-5.7% +2.0%
Year to date +69.7%+20.1%-32.7% +10.6%
1 year +85.6%+26.1%-50.7% +12.2%
3 years +367.8%+23.0%+175.0% +68.1%
3 years, per year +67.3%+7.1%+40.1% +18.9%
5 years +310.4%-68.4%+725.0% +61.4%
5 years, per year +32.7%-20.6%+52.6% +10.1%
10 years —-53.6%+120.0% +248.5%
10 years, per year —-7.4%+8.2% +13.3%

Risk

MeasureAMRXBHCELTPSPY
Volatility, 1Y 34.3%59.5%66.6% 13.6%
Downside volatility, 1Y 30.7%48.9%72.9% 13.9%
Beta vs S&P 500, 1Y 0.671.020.58 1.00
Return / volatility, 1Y 2.490.44-0.76 0.90
Max drawdown, 5Y -75.4%-84.7%-71.4% -25.4%
From 52-week high -1.5%-6.1%-51.5% -3.2%
52-week high $21.71$8.89$0.68 $779.14
52-week low $11.52$4.43$0.22 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMRXBHCELTP
P/E now vs peer median 53.8xmedian 17.0x -3.7xmedian 17.0x 5.9xmedian 17.0x
P/S now vs peer median 2.3xmedian 8.4x 0.3xmedian 8.4x 2.5xmedian 8.4x
EV/EBITDA now vs peer median 15.1xmedian 14.6x 8.6xmedian 14.6x 8.4xmedian 14.6x
P/FCF now vs peer median 193.9xmedian 19.0x 1.7xmedian 19.0x 40.8xmedian 19.0x
P/B now vs peer median 14.0xmedian 2.0x -2.4xmedian 2.0x 2.9xmedian 2.0x
PEG now vs peer median 0.65median 0.43 -0.65median 0.43 0.13median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMRXBHCELTP
Revenue $3.20B $11.11B $144.77M
Gross profit $1.29B $8.07B $63.22M
Operating income $478.99M $1.25B $36.65M
Net income $175.49M -$837.00M $60.28M
Free cash flow $38.42M $1.87B $8.72M
R&D $180.59M $638.00M $6.59M
EPS (diluted) $0.40 $-2.21 $0.05
Cash & equivalents $157.40M $2.49B $35.34M
Total debt $3.12B $20.64B $2.35M
Shares (diluted) 335.73M 380.70M 1.12B
Enterprise value $6.35B -$3.74B $274.64M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMRXBHCELTP
P/E 53.8x -3.7x 5.9x
P/FCF 193.9x 1.7x 40.8x
P/Operating cash flow 41.2x 1.4x 32.7x
P/S 2.3x 0.3x 2.5x
P/B 14.0x -2.4x 2.9x
P/Tangible book -7.3x -0.6x 3.0x
EV/EBITDA 15.1x 8.6x 8.4x
EV/EBIT 21.7x 17.1x 8.8x
EV/Revenue 3.3x 1.9x 2.2x
EV/FCF 271.0x 11.4x 37.0x
EV/Operating cash flow 57.6x 9.6x 29.7x
PEG (3Y EPS CAGR) 0.65 -0.65 0.13

Growth

14 metrics
MetricAMRXBHCELTP
Revenue growth (1Y) 8.9% 10.8% 17.8%
Revenue CAGR (3Y) 10.2% 9.2% 52.2%
Gross profit growth (1Y) 19.2% 13.9% -2.3%
Gross profit CAGR (3Y) 15.0% 10.2% 47.9%
Operating income growth (1Y) 33.8% -34.3% -13.1%
Operating income CAGR (3Y) 28.4% 50.6% 93.0%
Net income growth (1Y) 271.2% -345.5% 333.0%
Net income CAGR (3Y) 53.6% 5.3% 50.1%
EPS growth (1Y) 2,085% -329.1% 339.9%
EPS CAGR (3Y) 83.1% 5.7% 45.8%
Operating cash flow growth (1Y) -44.9% 46.7% -52.2%
Operating cash flow CAGR (3Y) -1.1% 25.5% 179.9%
Free cash flow growth (1Y) -84.6% 70.3% -59.7%
Free cash flow CAGR (3Y) -35.0% 25.9% 115.9%

Profitability

14 metrics
MetricAMRXBHCELTP
Gross margin 40.2% 72.6% 43.7%
EBITDA margin 21.5% 22.2% 26.4%
Operating margin 15.0% 11.2% 25.3%
Pretax margin 6.9% -3.2% 47.8%
Net margin 4.2% -7.6% 41.6%
FCF margin 1.2% 16.8% 6.0%
Operating cash flow margin 5.7% 19.9% 7.5%
Return on equity 74.3% – 53.1%
Return on assets 4.6% -3.3% 42.5%
Return on invested capital 14.3% 6.4% 27.6%
Return on capital employed 14.1% 6.1% 29.6%
Asset turnover 0.7x 0.4x 1.0x
Cash conversion (OCF / net income) 1.0x -2.6x 0.2x
Stock comp / revenue 1.2% 2.2% 0.1%

Financial Health

11 metrics
MetricAMRXBHCELTP
Debt / assets 59.2% 81.0% 1.6%
Debt / equity 5.9x -15.5x 0.0x
Net debt / EBITDA 4.3x 7.4x -0.9x
Debt / FCF 81.2x 11.1x 0.3x
Liabilities / assets 89.9% 105.2% 15.3%
Equity / assets 10.1% -5.2% 84.7%
Interest coverage – 0.8x 46.9x
Current ratio 1.9x 1.6x 6.7x
Quick ratio 1.1x 1.1x 5.4x
Cash ratio 0.1x 0.5x 1.9x
Altman Z-score 1.96 0.22 11.82

Shareholder Returns

7 metrics
MetricAMRXBHCELTP
Dividend yield – – –
Net buyback yield 0.0% – 0.0%
Shareholder yield 0.0% 0.0% 0.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMRXBHCELTP
Forward P/E 21.4xFY2026 1.6xFY2026 –
EPS, next fiscal year $1.00FY2026 $5.23FY2026 –
EPS growth, next FY +20.5%FY2026 +36.6%FY2026 –
EPS growth, the year after +26.0% -20.3% –
Revenue, next fiscal year $3.30BFY2026 $11.31BFY2026 –
Revenue growth, next FY +9.1%FY2026 +10.6%FY2026 –
Revenue growth, the year after +12.6% -1.5% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMRXBHCELTP
Held by institutions 51.0% 63.3% 0.0%
Institutions holding 310 221 1
Change in shares held, QoQ +1.3% +1.9% –
Institutions buying 182 99 1
Institutions selling 86 63 0
Buyers to sellers 2.12 1.57 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMRXBHCELTP
AMRX 1.00 0.14 -0.13
BHC 0.14 1.00 -0.02
ELTP -0.13 -0.02 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMRX, BHC and ELTP?

Amneal Pharmaceuticals (AMRX) is the largest by market capitalisation: Amneal Pharmaceuticals (AMRX) $7.12B, Bausch Health Companies (BHC) $3.18B, Elite Pharmaceuticals (ELTP) $401.23M.

Which stock is cheaper, AMRX, BHC and ELTP?

Elite Pharmaceuticals (ELTP) trades on the lowest price-to-earnings ratio (Amneal Pharmaceuticals (AMRX) 53.4x, Bausch Health Companies (BHC) -3.8x, Elite Pharmaceuticals (ELTP) 6.7x). On next year's consensus earnings, Bausch Health Companies (BHC) is cheapest (Amneal Pharmaceuticals (AMRX) 21.4x, Bausch Health Companies (BHC) 1.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Elite Pharmaceuticals (ELTP) grew revenue fastest over the trailing twelve months: Amneal Pharmaceuticals (AMRX) +8.9%, Bausch Health Companies (BHC) +10.8%, Elite Pharmaceuticals (ELTP) +17.8%.

Which company is more profitable?

Elite Pharmaceuticals (ELTP) has the highest net margin (Amneal Pharmaceuticals (AMRX) 4.2%, Bausch Health Companies (BHC) -7.6%, Elite Pharmaceuticals (ELTP) 41.6%). On return on invested capital, Elite Pharmaceuticals (ELTP) leads (Amneal Pharmaceuticals (AMRX) 14.3%, Bausch Health Companies (BHC) 6.4%, Elite Pharmaceuticals (ELTP) 27.6%).

Which stock has performed better?

Over the past year Amneal Pharmaceuticals (AMRX) returned the most: Amneal Pharmaceuticals (AMRX) +85.6%, Bausch Health Companies (BHC) +26.1%, Elite Pharmaceuticals (ELTP) -50.7%. Over five years, Elite Pharmaceuticals (ELTP) compounded fastest (Amneal Pharmaceuticals (AMRX) +32.7%/yr, Bausch Health Companies (BHC) -20.6%/yr, Elite Pharmaceuticals (ELTP) +52.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Amneal Pharmaceuticals (AMRX) has been the steadiest (Amneal Pharmaceuticals (AMRX) 34.3%, Bausch Health Companies (BHC) 59.5%, Elite Pharmaceuticals (ELTP) 66.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AMRX, BHC and ELTP?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Elite Pharmaceuticals (ELTP) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.